China Medical & HealthCare : INSIDE INFORMATION (in PDF)

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

China Medical & HealthCare Group Limited

(Incorporated in Bermuda with limited liability)

(Stock Code: 383) INSIDE INFORMATION

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the shareholders of the Company and potential investors that based on its preliminary review on the relevant unaudited consolidated management accounts of the Group for the eleven months ended 31 May 2017 and information currently available, it is expected to record a significant decrease in the loss attributable to the shareholders of the Company for the year ended 30 June 2017 as compared with 2016. The expected significant decrease in loss attributable to the shareholders of the Company for the year ended 30 June 2017 was mainly due to the realized and mark-to-market unrealized gains from investments held for trading and derivative financial instruments as compared with realized and mark-to-market unrealized losses recorded in 2016, which were partially off-set by the loss on disposal of a subsidiary.

Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.

This announcement is made by China Medical & HealthCare Group Limited (the "Company", together with its subsidiaries, collectively the "Group") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong) (the "SFO").

The board of the directors of the Company (the "Board") wishes to inform the shareholders of the Company and potential investors that based on its preliminary review on the relevant unaudited consolidated management accounts of the Group for the eleven months ended 31 May 2017 and information currently available, it is expected to record a significant decrease in the loss attributable to the shareholders of the Company for the year ended 30 June 2017 as compared with 2016. The expected significant decrease in loss attributable to the shareholders of the Company for the year ended 30 June 2017 was mainly due to the realized and mark-to- market unrealized gains from investments held for trading and derivative financial instruments as compared with realized and mark-to-market unrealized losses recorded in 2016, which were partially off-set by the loss on disposal of a subsidiary.

This inside information announcement is only based on the preliminary review on the relevant unaudited consolidated management accounts of the Group for the eleven months ended 31 May 2017 and the information currently available, which have not been confirmed or reviewed by the Company's auditor. The Company is in the process of finalizing the annual results for the year ended 30 June 2017 and the shareholders of the Company and potential investors are advised to read carefully the annual results announcement of the Company for the year ended 30 June 2017, which is expected to be released before the end of September 2017.

Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.

By Order of the Board

China Medical & HealthCare Group Limited Dr. Lim Cheok Peng

Chairman

Hong Kong, 19 July 2017

As at the date of this announcement, the Board comprises: - Executive Directors

Ms. Chong Sok Un (Deputy Chairman), Dr. Jonathan Weiyan Seah (Chief Executive Officer), Dato' Wong Peng Chong and Mr. Kong Muk Yin

Non-Executive Directors

Dr. Lim Cheok Peng (Chairman) and Mr. Liao Feng

Independent Non-Executive Directors

Mr. Lau Siu Ki, Mr. Zhang Jian and Dr. Xia Xiaoning